|
FDA Panel Recommends InterMune Drug Approval for Lung Disease
An FDA advisory panel voted 9–3 to recommend approval of InterMune’s Esbriet to slow the decline in lung function in patients with idiopathic
pulmonary fibrosis (IPF), despite agency staff concerns about proof of efficacy.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives